Bosutinib: A dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia

Expert Review of Hematology

Volumn 2, Issue 5, 2009, Pages 489-497

  Keller, Gunhild ^a   Schafhausen, Philippe ^a   Brummendorf, Tim H ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

BCR ABL; Bosutinib; CML; Dasatinib; Imatinib; Nilotinib; Point mutation; SRC; SRC ABL kinase inhibitor; Tyrosine kinase

Indexed keywords

ABELSON KINASE; BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE;

ABDOMINAL PAIN; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BACKACHE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FATIGUE; FEVER; FLUID RETENTION; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; NAUSEA; NEUTROPENIA; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NITRILES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; QUINOLINES; SRC-FAMILY KINASES;

EID: 77953440232     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.09.42     Document Type: Review

References (41)

1. Sattler M, Scheijen B, Weisberg E, Griffin JD. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias. Adv. Exp. Med. Biol. 532, 121-140 (2003).
2. Buchdunger E, Zimmermann J, Mett H et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56(1), 100-104 (1996).
3. Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J. Clin. Oncol. 21(8), 1637-1647 (2003).
4. O'Brien SG, Guilhot F, Goldman JM et al. International Randomized Study of Interferon Versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Proc. Am. Soc. Hematol. (2008) (Abstract 186).
5. Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a Phase II study. Blood 99(10), 3530-3539 (2002). (Pubitemid 34534519)
6. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105(7), 2640-2653 (2005).
7. Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101(11), 4611-4614 (2003).
8. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305(5682), 399-401 (2004).
9. Kantarjian HM, Giles F, Gattermann N et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110(10), 3540-3546 (2007).
10. Kantarjian H, Pasquini R, Hamerschlak N et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized Phase 2 trial. Blood 109(12), 5143-5150 (2007). (Pubitemid 46890528)
11. Brave M, Goodman V, Kaminskas E et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin. Cancer Res. 14(2), 352-359 (2008).
12. Hochhaus A, Kantarjian HM, Baccarani M et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109(6), 2303-2309 (2007). (Pubitemid 46425867)
13. Shah NP, Kantarjian HM, Kim DW et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J. Clin. Oncol. 26(19), 3204-3212 (2008).
14. Boschelli DH, Ye F, Wang YD et al. Optimization of 4-phenylamino-3- quinolinecarbonitriles as potent inhibitors of Src kinase activity. J. Med. Chem. 44(23), 3965-3977 (2001).
15. Boschelli DH. Exploitation of the 3-quinolinecarbonitrile template for SRC tyrosine kinase inhibitors. Curr. Top. Med. Chem. 8(10), 922-934 (2008).
16. Puttini M, Coluccia AM, Boschelli F et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinibresistant Bcr-Abl+ neoplastic cells. Cancer Res. 66(23), 11314-11322 (2006).
17. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu. Rev. Cell. Dev. Biol. 13, 513-609 (1997).
18. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 22(4), 337-358 (2003).
19. Johnson FM, Gallick GE. SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med. Chem. 7(6), 651-659 (2007).
20. Li S. Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk. Lymphoma 49(1), 19-26 (2008).
21. Golas JM, Lucas J, Etienne C et al. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res. 65(12), 5358-5364 (2005).
22. Laneuville P. Abl tyrosine protein kinase. Semin. Immunol. 7(4), 255-266 (1995).
23. Pendergast AM. Nuclear tyrosine kinases: from Abl to WEE1. Curr. Opin. Cell Biol. 8(2), 174-181 (1996).
24. Chung SW, Daniel R, Wong BY, Wong PM. The ABL genes in normal and abnormal cell development. Crit. Rev. Oncog. 7(1-2), 33-48 (1996).
25. Golas JM, Arndt K, Etienne C et al. SKI-606, a 4-anilino-3- quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 63(2), 375-381 (2003).
26. Remsing Rix LL, Rix U, Colinge J et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 23(3), 477-485 (2009).
27. Mancini M, Brusa G, Zuffa E et al. Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606. Leuk. Res. 31(7), 979-987 (2007).
28. Redaelli S, Piazza R, Rostagno R et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J. Clin. Oncol. 27(3), 469-471 (2009).
29. Cortes J, Kantarjian HM, Kim DW et al. Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib. Proc. Am. Soc. Hematol. (2008) (Abstract 1098).
30. Gambacorti-Passerini C, Pogliani EM, Baccarani M et al. Bosutinib (SKI-606) Demonstrates clinical activity and is well tolerated in patients with AP and BP CML and Ph+ ALL. Proc. Am. Soc. Hematol. (2008) (Abstract 1101).
31. Quintas-Cardama A, Cortes J. Management of patients with resistant or refractory chronic myelogenous leukemia. Oncology (Williston Park) 22(4), 430-437 (2008).
32. Quintas-Cardama A, Cortes J. Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones. Leuk. Res. 32(8), 1313-1316 (2008).
33. Bartolovic K, Balabanov S, Hartmann U et al. Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 103(2), 523-529 (2004).
34. Konig H, Holyoake TL, Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 111(4), 2329-2338 (2008).
35. Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc. Natl Acad. Sci. USA 103(45), 16870-16875 (2006).
36. Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat. Med. 10(11), 1187-1189 (2004).
37. Copland M, Hamilton A, Elrick LJ et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107(11), 4532-4539 (2006).
38. Gleixner KC, Remsing LL, Baumgartner C et al. Effects of bosutinib (SKI-606) in CML: kinase target profile, effects on bcr/ abl mutants, and synergism with dasatinib in T315I+ cells. Proc. Am. Soc. Hematol. (2008) (Abstract 3195).
39. Gontarewicz A, Balabanov S, Keller G et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 111(8), 4355-4364 (2008).
40. O'Hare T, Eide CA, Deininger MW. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. Expert Opin. Investig. Drugs 17(6), 865-878 (2008).
41. Essers MA, Offner S, Blanco-Bose WE et al. IFNa activates dormant haematopoietic stem cells in vivo. Nature 458(7240), 904-908 (2009).